New agent overcomes resistance to imatinib
A drug that can overcome resistance to imatinib in patients with chronic myelogenous leukaemia (CML) has been developed by US researchers (Proc Natl Acad Sci USA, published online Jan 27, 2005, DOI: 10.1073/pnas.0408283102). Imatinib selectively inhibits BCR-ABL tyrosine kinase in CML cells, but some tumour cells acquire resistance to imatinib because of mutations in the kinase domain of BCR-ABL.
(2005). New agent overcomes resistance to imatinib. Lancet Oncology, 6(3), 137.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/445